ArticleFrontiers in pharmacology2026

Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system.

Feng Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.